ClinicalTrials.gg
RecruitingNCT06258408Updated Nov 17, 2025

A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of BB102 tablet in Advanced Solid Tumor, sponsored by Broadenbio Ltd., Co.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Broadenbio Ltd., Co. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Dec 2022, registered Feb 2024).
  • Started Dec 2022; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Not applicable
Ages
18 Years to 78 Years
Sex
All
01

Study summary

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced solid tumors. This study has two phase: dose escalation phase and expansion phase.

Read the detailed description

This first-in-human (FIH) study of BB102 will evaluate safety, tolerability, pharmacokinetics (PK), efficacy and preliminary food effect in subjects with advanced solid tumors. In dose escalation trial, the primary objective is to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of BB102 as monotherapy, and to evaluate the safety and tolerability of BB102. The secondary objectives include the assessments of PK profile, preliminary efficacy, preliminary food effect (FE), preliminary metabolites identification, biomarkers and C-QTcF analysis of BB102. In expansion trial, the primary objective is to evaluate the efficacy of BB102 in subjects with FGF19 or FGFR4 positive advanced primary hepatocellular carcinoma (HCC) or other advanced solid tumors. The secondary objectives include the assessments of PK profile, safety and biomarkers of BB102.

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • BB102
  • FGFR4
  • First-in-Human
  • Dose Escalation
  • FGF19
03

In context

Lead sponsor

Broadenbio Ltd., Co. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. For the dose escalation trial, histologically, confirmed or clinically confirmed advanced solid tumors patients who without available standard treatment, have disease progression on standard treatment or cannot tolerate standard treatment.

    For the expansion trial, histologically or cytologically confirmed FGF19 or FGFR4 positive advanced primary HCC or other advanced solid tumors patients who without available standard treatment, have disease progression on standard treatment or cannot tolerate standard treatment.

  2. For the dose escalation trial, at least one evaluable lesion as defined by v1.1.

    For the expansion trial, at least one as defined by RECIST v1.1.

  3. (ECOG) score ≤1.
  4. Expected survival ≥ 3 months.
  5. Adequate organ function.
  6. Female subjects of must have a negative pregnancy test prior to the first dose and are required to use effective from signing the ICF until 6 months after the last dose of study treatment.
  7. Fully informed of the study and voluntarily signed the form (ICF), and willing to follow and have the ability to complete all trial procedures.

Exclusion criteria

Exclusion Criteria:

  1. Use of systemic or systemic cortisol (≥10 mg prednisone or other equivalent hormones) within 4 weeks.
  2. Prior use of selective FGFR4 inhibitor and/or pan-FGFR inhibitor therapy.
  3. Use of cytotoxic chemotherapeutics within 4 weeks, OR use of state-approved Chinese traditional patent drugs/Chinese traditional drugs with an antitumor effect within 2 weeks.
  4. Anti-tumor endocrine therapy, radiotherapy, interventional embolization, radiofrequency, proton therapy, radioimmunotherapy, immunotherapy or other biotherapies within 4 weeks.
  5. Use of other clinical drug or therapy that was not marketed within 4 weeks.
  6. The patient is receiving drugs or therapies prohibited in the protocol and cannot discontinue such use at least 2 weeks.
  7. Pregnant or lactating females.
  8. Presence of gastrointestinal disorder that may affect the intake, transport, or absorption of the study drug at screening.
  9. Patient with dual-source cancer within 5 years.
  10. Presence of clinically symptomatic to the central nervous system or meninges or other evidence showing that metastatic lesions in the central nervous system or meninges have not yet been controlled at screening, which, at the investigator's discretion, is not suitable for enrollment.
  11. History of severe neurological or psychiatric disorders, including epilepsy, dementia, moderate to severe depression, etc.
  12. Clinically significant and uncontrolled cardiovascular diseases.
  13. Pulmonary embolism within 6 months.
  14. Prior stem cell transplantation, bone marrow transplantation or vital organ transplantation.
  15. Presence of uncontrollable infectious disease, congenital immunodeficiency disease,acquired immunodeficiency syndrome, syphilis, active , virus (HCV) infection.
  16. Severe active infection, including but not limited to bacteremia, severe pneumonia, etc., occurred within 2 weeks; an active infection that received therapeutic intravenous antibiotics within 2 weeks.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    BB102 monotherapy

    The study is composed of fasted dose cohorts and fed dose cohort. BB102 will be administered orally daily alone as monotherapy in all cohorts. In the fasted dose cohorts, the subjects will receive once daily of BB102 monotherapy fasted across approximately 6 ascending dose levels. The starting dose is 50mg/day. In the fed dose cohort, the subjects will receive once daily of BB102 monotherapy in a fed condition. The dose selected for fed dose cohort must be deemed safe as assessed by safety monitoring committee (SMC).

    Drug: BB102 tablet

Interventions

  • DrugBB102 tablet

    BB102 tablets will be administered orally once daily(QD).

    Also known as: BB102

06

What researchers measure

Primary outcomes

  1. Number of subjects with dose limiting toxicities (DLTs)

    To assess the safety and tolerability of BB102 tablet as monotherapy in subjects with advanced solid tumors and to determine the maximum tolerated dose (MTD) of BB102 tablet, and to provide a basis for determination of the recommended dose (RP2D) for Phase II clinical trials.

    Time frame: Single dose to the end of Cycle 1 (each cycle is 21 days)

  2. Number of subjects with adverse events (AEs) and serious adverse events (SAEs)

    AEs and SAEs will be characterized by type, seriousness, relationship to study treatment, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] version 5.0) and timing. FGF19 or FGFR4 positive advanced primary HCC or other advanced solid tumors.

    Time frame: From screening (Day -28 to Day -1) through up to 12 months or until disease progression

Secondary outcomes

  1. Pharmacokinetic Assessments: Peak Plasma Concentration (Cmax)

    Blood samples will be collected for PK analyses

    Time frame: Day 1, Day 8, Day 15 and at the end of Cycle 1 (each cycle is 21 days)

  2. Pharmacokinetic Assessments: Time to Peak Concentration (Tmax)

    Blood samples will be collected for PK analyses

    Time frame: Day 1, Day 8, Day 15 and at the end of Cycle 1 (each cycle is 21 days)

  3. Pharmacokinetic Assessments: Area under the plasma concentration-time curve (AUC)

    Blood samples will be collected for PK analyses

    Time frame: Day 1, Day 8, Day 15 and at the end of Cycle 1 (each cycle is 21 days)

  4. Pharmacokinetic Assessments: Elimination half-life (t½)

    Blood samples will be collected for PK analyses

    Time frame: Day 1, Day 8, Day 15 and at the end of Cycle 1 (each cycle is 21 days)

  5. Objective response rate (ORR)

    Tumor response measured by radiologic imaging techniques at baseline and throughout the study.

    Time frame: From date of screening until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  6. Duration of response (DOR)

    Tumor response measured by radiologic imaging techniques at baseline and throughout the study.

    Time frame: From date of screening until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  7. Disease control rate (DCR)

    Tumor response measured by radiologic imaging techniques at baseline and throughout the study.

    Time frame: From date of screening until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  8. Progression-free survival (PFS)

    Tumor response measured by radiologic imaging techniques at baseline and throughout the study.

    Time frame: From date of screening until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Dec 2026, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2024
First posted
Feb 14, 2024
StartActual
Dec 29, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06258408
Lead sponsor
Broadenbio Ltd., Co.
Responsible party
Sponsor
First posted
Feb 14, 2024
Start date
Dec 29, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 17, 2025

Study contacts

Qi Wang, PhD
Contact
qi.wang@broadenbio.com
+86-15311443674
Suxia Luo, MD
principal investigator · Henan Cancer Hospital

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion